Dr. Michael M. Haddadin, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 121
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NE license 35770
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Bryan Medical Center Lincoln, NE
- Bellevue Medical Center Bellevue, NE
Medical groups
- Unmc Physicians (1,518 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 121
- Services billed
- 850
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 69 | 17 |
| Established patient office or other outpatient visit, 40-54 minutes | 23 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Omaha, NE | 73 |
| Levofloxacin Other prescribers in Omaha, NE | 47 |
| Sprycel (dasatinib) | 29 |
| Voriconazole | 22 |
| Fluconazole Other prescribers in Omaha, NE | 20 |
| Posaconazole | 20 |
| Allopurinol Other prescribers in Omaha, NE | 19 |
| Venclexta (venetoclax) | 17 |
| Eliquis (apixaban) Other prescribers in Omaha, NE | 15 |
| Hydroxyurea Other prescribers in Omaha, NE | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 27 payments worth $6,550 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $3,046 |
|---|---|
| Adaptive Biotechnologies Corporation | $1,442 |
| Celgene Corporation | $1,213 |
| Incyte Corporation | $250 |
| Geron Corporation | $226 |
| E.r. Squibb & Sons, L.l.c. | $130 |
| Sanofi US Services Inc. | $125 |
| Amgen Inc. | $74.02 |
| Consulting Fee | $2,780 |
|---|---|
| Travel and Lodging | $2,386 |
| Food and Beverage | $1,385 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Dec 4, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,780 |
| Celgene Corporation Oct 16, 2025 | Travel and Lodging travel to Aurora, CO | $627 |
| Celgene Corporation Oct 15, 2025 | Travel and Lodging travel to Aurora, CO | $554 |
| Adaptive Biotechnologies Corporation Mar 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $483 |
| Adaptive Biotechnologies Corporation Mar 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $449 |
| E.r. Squibb & Sons, L.l.c. Nov 4, 2025 | Travel and Lodging travel to AURORA, CO | $96.01 |
| Adaptive Biotechnologies Corporation Mar 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $86.41 |
| Adaptive Biotechnologies Corporation Mar 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $57.00 |
| E.r. Squibb & Sons, L.l.c. Nov 4, 2025 | Travel and Lodging travel to AURORA, CO | $33.83 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $95,823 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.